Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NL-17
- Development stage
- Preclinical
- Lead developer
- Neurocarrus
- Modality
- Recombinant Proteins and Enzymes
01
Overview
NL-17 is an engineered recombinant protein biologic currently in preclinical development by Neurocarrus for the prevention of migraine. The therapeutic is designed to specifically target sensory neurons to control migraine pain signaling. By modulating the activity of these neurons, NL-17 aims to provide a targeted approach to migraine management, potentially offering a long-acting solution with a favorable safety profile by minimizing off-target effects in the central nervous system or other tissues.
Beyond the preview
Go deeper on NL-17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NL-17.